Piper Sandler analyst Biren Amin lowered the firm’s price target on Sarepta (SRPT) to $182 from $200 and keeps an Overweight rating on the shares. The company announced a significant collaboration with Arrowhead (ARWR) in which it acquired four clinical stage pipeline programs spanning neuromuscular, pulmonary, and central nervous system, and in addition three preclinical CNS programs and six discovery programs, the analyst tells investors in a research note. The firm says deal “broadens and deepens” Sarepta’s pipeline. Piper added the $500M in upfront expense, along with $50M per year for five years, and $300M in near-term milestone payments to its model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target raised to $217 from $210 at BofA
- Trump threatens tariffs, Zoom reports Q3 beat: Morning Buzz
- Sarepta deal with Arrowhead a ‘prudent move,’ says Leerink
- Sarepta deal with Arrowhead creates major catalysts, says BMO Capital
- Morning Movers: Dick’s Sporting jumps and Kohl’s sinks following earnings